Armistice Capital, LLC 13D and 13G filings for BioXcel Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-15 11:09 am Purchase | 2026-03-31 | 13G | BIOXCEL THERAPEUTICS INC N BTAI | Armistice Capital, LLC | 1,910,076 7.050% | 1,621,945 (+562.92%) | Filing |
| 2025-05-15 3:33 pm Sale | 2025-03-31 | 13G | BIOXCEL THERAPEUTICS INC N BTAI | Armistice Capital, LLC | 288,131 4.990% | -4,709,144 (-94.23%) | Filing |
| 2025-02-14 5:27 pm Purchase | 2024-12-31 | 13G | BIOXCEL THERAPEUTICS INC N BTAI | Armistice Capital, LLC | 4,997,275 9.990% | 4,997,275 (New Position) | Filing |